All In Biotech

Drug Trial Radar · NCT07896005

A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer

A Randomized, Controlled, Open-label, Multicenter Phase III Study of SHR-A1811 Combined With Adebrelimab for the First-line Treatment of Patients With HER2-overexpressing Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 436 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

436

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Feb 2031

Study completion Mar 2032

Sponsor

Sponsor type
Industry
First posted
Oct 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open-label, multicenter, phase 3 clinical study comparing the efficacy and safety of SHR-A1811 in combination with Adebrelimab versus platinum-based doublet chemotherapy in combination with Tislelizumab as first-line treatment in patients with HER2-overexpressing locally advanced or metastatic non-squamous non-small cell lung cancer.

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • SHR-A1811 InjectionDrug

    SHR-A1811 Injection.

  • Adebrelimab InjectionDrug

    Adebrelimab Injection.

  • Tislelizumab InjectionDrug

    Tislelizumab Injection.

  • Pemetrexed Disodium For InjectionDrug

    Pemetrexed Disodium For Injection.

  • Carboplatin injectionDrug

    Carboplatin Injection.

  • Cisplatin injectionDrug

    Cisplatin Injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) based on blinded independent central review (BICR)Time frame: From randomization until disease progression or death from any cause, whichever occurs first, up to approximately 40 months.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.